Richard M. Lee‐Ying

PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium

Dominick Bossé, Jamison Mercer, Soundouss Raissouni et al. · Clinical Colorectal Cancer · 2016 · 71 citations

Surgical Oncology, Patient Selection, Medicine +8

The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study

Jeenan Kaiser, Haocheng Li, Scott North et al. · Bladder Cancer · 2018 · 26 citations · Full text

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab

Andrea S. Fung, Vincent C. Tam, Daniel E. Meyers et al. · Cancer Medicine · 2020 · 23 citations · Full text

Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world

Mita Manna, Richard M. Lee‐Ying, Gwynivere A Davies et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 22 citations

Lymphoid Neoplasia, Transplantation, Autoimmune Disease +14

Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database

Haider Samawi, Hao‐Wen Sim, Kelvin Chan et al. · Cancer Medicine · 2018 · 20 citations · Full text

Cancer Management, Prognosis, Pathology +16